Loading this company
Ascendis Pharma A/S
ASNDPrices in USD
TickerWorth ScoreC50/100
What we think
We do not publish a fair value for this company. The grade still applies.
Price
$229.91USD up +$4.66 (+2.07%)
Quoted · Prices are delayed.
Showing the last price we hold for this listing, recorded 2026-10-19 15:42 UTC (4 hours ago).
Why did it move today?
Nothing we can cite explains today’s move for this company.
We do not put a fair value on this one
Our cash-flow model doesn't produce a meaningful value for this business — its projected free cash flow is so far from supporting the current price that the result is effectively zero, which tells you about the limits of the model on a fast-growing or loss-making company, not about what the business is worth. Here is what we can show instead.
Is it a good business?
- Valuation50 out of 100
- Growth75 out of 100
- Financial health100 out of 100
- Past performance100 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$306.21 across 21 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It operates in the Biotechnology industry (Healthcare sector), headquartered in Denmark. The company employs roughly 1,189 people.
Key stats
52-week range$186.05–$282.15
- Open
- $228.48
- Day high
- $230.51
- Day low
- $225.81
- Previous close
- $225.25
- Volume
- 417,606 · 0.61× avg
- Average volume
- 679,454
- Market cap
- $15,128,586,240.00
- P/E (TTM)
- 17.62
- Earnings per share
- $13.05
- Beta
- —
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
No filings or corporate activity on file in the recent window.
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Bodenhoff MadsOption exercise · $330,000.00
- Bodenhoff MadsOpen-market sale ·
Not investment advice. TickerWorth Score is a model output.